Vyndamax has been on the market since May of 2019.
The U.S. Food and Drug Administration also known as the FDA approved Vyndamax for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Vyndamax was approved around the same time as a similar formulated drug called Vyndaqel, although Pfizer planned to transition any patients to the single capsule Vyndamax, which then became available in the latter half of the year 2019.
The list price for the drug Vyndamax is over $21,800.00 per month, although the out-of-pocket cost can also vary significantly based on your health insurance.
Commercially health insured patients may pay as little as $0 per month for Vyndamax through a co-pay savings program, while Medicare patients can have their annual out-of-pocket cost for Vyndamax capped at $2,000.00 for all their Part D medications.
Vyndamax is a prescription medicine that is used to treat adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.
Although it is not known if Vyndamax is safe and effective in children.
And two out of every five patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis (Vyndamax and Vyndaqel; Pfizer) can be expected to die in less than 4 years.
Transthyretin amyloidosis (ATTR-CM) is a disease in which a misfolded protein, transthyretin (TTR), builds up as amyloid deposits in the heart muscle, causing it to become stiff and unable to pump blood effectively.
Symptoms of transthyretin amyloidosis (ATTR-CM) include shortness of breath, swelling in the legs and feet, fatigue, and an irregular heart rate.
Diagnosis for transthyretin amyloidosis (ATTR-CM) involves imaging and sometimes genetic testing, and treatment focuses on slowing disease progression through medication like tafamidis.